Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib for Recurrent High-grade Glioma
NCT03390062Phase 2Unknown
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of Rivoceranib in glioma, sponsored by West China Hospital of Sichuan University. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT03390062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03390062.